Attractive Stocks Alert: MannKind (NASDAQ: MNKD), Gilead Sciences, Inc …iStreetWireElotuzumab, for instance, is associated with Bristol-Myers Squibb (BMY), while Daclizumab is being developed with Biogen Idec. AbbVie Inc (NYSE:ABBV) ranged in price b…
Vaccine antibodies correlated with protection against HSV-1HealioAntibodies to herpes simplex virus type 2 glycoprotein D correlated with protection against herpes simplex virus type 1, researchers reported in The Journal of Infectious Diseases. In a p…
MedscapeIs Obinutuzumab the Drug to Watch in CLL?MedscapeMaintenance therapy in follicular lymphoma — for example, the PRIMA study and the SAKK study, in which different durations of continuous rituximab were applied — there were some updates of thes…
Barron’s (blog)AbbVie: No Upside For Hep-C, Little Upside For Stock, Morgan Stanley SaysBarron’s (blog)Elotuzumab, for instance, is partnered with Bristol-Myers Squibb (BMY), while Daclizumab is being developed with Biogen Idex (BIIB). Shares of AbbVie…
|
Shopping for Biotech Growth Names: Reni Benjamin
Trefis However, the standard of care for CLL is FCR—fludarabine, cytarabine and rituximab (Rituxan). The fludarabine/cytarabine is the chemotherapy part and rituximab is the monoclonal antibody. Pharmacyclics has shown a significant benefit in CLL using just … |
OncLiveAnticancer Antibodies Pose Complex Challenges for Drugmakers: An Interview …OncLiveAnticancer Antibodies Pose Complex Challenges for Drugmakers: An Interview With Martin Van Trieste. Anita T. Shaffer. Published Online: Wednesday, December 18, …
MedscapeNovel Agents: Making the Benefit Last in CLLMedscapeBruce D. Cheson, MD: Hello. I am Bruce Cheson, Deputy Chief of Hematology-Oncology, and Head of Hematology at Georgetown University Hospital at the Lombardi Comprehensive Cancer Center in Wash…
|
Los fármacos que vienen para la esclerosis múltiple
El Correo Daclizumab es otro de los anticuerpos monoclonales que se administra cada cuatro semanas, vía subcutánea. Hasta ahora sus resultados en ensayos clínicos (SELECT, DECIDE) “han sido francamente buenos”. Por otra parte, el medicamento ocrelizumab … |
|
Los fármacos que vienen para la esclerosis múltiple
El Diario Montanes Daclizumab es otro de los anticuerpos monoclonales que se administra cada cuatro semanas, vía subcutánea. Hasta ahora sus resultados en ensayos clínicos (SELECT, DECIDE) “han sido francamente buenos”. Por otra parte, el medicamento ocrelizumab … |
India.Com HealthNewly discovered antibodies raise HIV vaccine hopesFinancial ExpressDr Wayne Koff, chief scientific officer in IAVI and a leading figure in the AIDS vaccine research, said scientists have isolated, from HIV-positive donors around the wo…